These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

500 related items for PubMed ID: 16448896

  • 1. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity.
    Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB.
    Am J Hypertens; 2006 Feb; 19(2):214-9. PubMed ID: 16448896
    [Abstract] [Full Text] [Related]

  • 2. The angiotensin receptor blocker eprosartan mesylate reduces pulse pressure in isolated systolic hypertension.
    Teitelbaum I, Chilvers M, Reiz RJ.
    Can J Cardiol; 2004 Oct; 20 Suppl C():11C-16C. PubMed ID: 16807618
    [Abstract] [Full Text] [Related]

  • 3. Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study.
    Punzi HA, Punzi CF.
    J Hum Hypertens; 2004 Sep; 18(9):655-61. PubMed ID: 15042114
    [Abstract] [Full Text] [Related]

  • 4. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
    Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M, CAFE Investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators, CAFE Steering Committee and Writing Committee.
    Circulation; 2006 Mar 07; 113(9):1213-25. PubMed ID: 16476843
    [Abstract] [Full Text] [Related]

  • 5. The effect of treatment with eprosartan on pulse pressure: factors predicting response.
    de la Sierra A, Muñoz A, Arcos E, López JS, Relats J, ETAPA-2 study investigators.
    Can J Cardiol; 2004 Oct 07; 20 Suppl C():17C-22C. PubMed ID: 16807619
    [Abstract] [Full Text] [Related]

  • 6. Different influences on central and peripheral pulse pressure, aortic wave reflections and pulse wave velocity of three different types of antihypertensive drugs.
    Polónia J, Barbosa L, Silva JA, Maldonado J.
    Rev Port Cardiol; 2003 Dec 07; 22(12):1485-92. PubMed ID: 15008064
    [Abstract] [Full Text] [Related]

  • 7. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
    Levine B.
    Curr Med Res Opin; 2001 Dec 07; 17(1):8-17. PubMed ID: 11464450
    [Abstract] [Full Text] [Related]

  • 8. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers.
    Polónia J, Barbosa L, Silva JA, Bertoquini S.
    Blood Press Monit; 2010 Oct 07; 15(5):235-9. PubMed ID: 20577082
    [Abstract] [Full Text] [Related]

  • 9. A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a beta-blocker on blood pressure reduction.
    Wald DS, Law M, Mills S, Bestwick JP, Morris JK, Wald NJ.
    Clin Ther; 2008 Nov 07; 30(11):2030-9. PubMed ID: 19108791
    [Abstract] [Full Text] [Related]

  • 10. Blood pressure response under chronic antihypertensive drug therapy: the role of aortic stiffness in the REASON (Preterax in Regression of Arterial Stiffness in a Controlled Double-Blind) study.
    Protogerou A, Blacher J, Stergiou GS, Achimastos A, Safar ME.
    J Am Coll Cardiol; 2009 Feb 03; 53(5):445-51. PubMed ID: 19179203
    [Abstract] [Full Text] [Related]

  • 11. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension.
    Mahmud A, Feely J.
    Am J Hypertens; 2005 Jan 03; 18(1):50-5. PubMed ID: 15691617
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients.
    Robles NR, Martín-Agueda B, López-Muñoz F, Alamo C, Investigators of the ESTEPP Study.
    Int J Clin Pract; 2005 Apr 03; 59(4):478-84. PubMed ID: 15853868
    [Abstract] [Full Text] [Related]

  • 13. Eprosartan mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting.
    Conter HS, McKay DW, Reiz RJ.
    Can J Cardiol; 2004 Oct 03; 20 Suppl C():6C-10C. PubMed ID: 16807617
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness of eprosartan in diabetic hypertensive patients.
    Robles NR, Martín-Agueda B, López-Muñoz F, Alamo C, Investigators of ESTEPP Study.
    Eur J Intern Med; 2008 Jan 03; 19(1):27-31. PubMed ID: 18206598
    [Abstract] [Full Text] [Related]

  • 15. Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
    Ram CV, Rudmann MA.
    Expert Rev Cardiovasc Ther; 2007 Nov 03; 5(6):1003-11. PubMed ID: 18035916
    [Abstract] [Full Text] [Related]

  • 16. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection.
    Mahmud A, Feely J.
    Am J Hypertens; 2008 Jun 03; 21(6):663-7. PubMed ID: 18437130
    [Abstract] [Full Text] [Related]

  • 17. Do losartan and atenolol have differential effects on BNP and central haemodynamic parameters?
    Davies J, Carr E, Band M, Morris A, Struthers A.
    J Renin Angiotensin Aldosterone Syst; 2005 Dec 03; 6(3):151-3. PubMed ID: 16525946
    [Abstract] [Full Text] [Related]

  • 18. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB, de Faire U, Fyhrquist F, Harris KE, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Hille DA, Dahlöf B.
    Curr Med Res Opin; 2007 Feb 03; 23(2):259-70. PubMed ID: 17288679
    [Abstract] [Full Text] [Related]

  • 19. Noninvasive pulse waveform analysis in clinical trials: similarity of two methods for calculating aortic systolic pressure.
    Adji A, Hirata K, Hoegler S, O'Rourke MF.
    Am J Hypertens; 2007 Aug 03; 20(8):917-22. PubMed ID: 17679043
    [Abstract] [Full Text] [Related]

  • 20. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study.
    Hanon O, Berrou JP, Negre-Pages L, Goch JH, Nádházi Z, Petrella R, Sedefdjian A, Sévenier F, Shlyakhto EV, Pathak A.
    J Hypertens; 2008 Aug 03; 26(8):1642-50. PubMed ID: 18622244
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.